玻璃体内注射贝伐单抗（阿瓦斯汀）安全吗？
Is intravitreal bevacizumab (Avastin) safe?
作者信息
Michels S
出版信息
Br J Ophthalmol. 2006 Nov;90(11):1333-4. doi: 10.1136/bjo.2006.102293.
Abstract
Can a drug be safe if an FDA warning has been issued for it?
摘要
如果一种药物已收到美国食品药品监督管理局（FDA）的警告，它还能是安全的吗？
相似文献
1
Is intravitreal bevacizumab (Avastin) safe?玻璃体内注射贝伐单抗（阿瓦斯汀）安全吗？
Br J Ophthalmol. 2006 Nov;90(11):1333-4. doi: 10.1136/bjo.2006.102293.
2
Intravitreal bevacizumab.玻璃体内注射贝伐单抗。
Ophthalmology. 2007 Feb;114(2):400; author reply 400-1. doi: 10.1016/j.ophtha.2006.10.002.
3
Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia.玻璃体内注射贝伐单抗治疗病理性近视性脉络膜新生血管
Retina. 2006 Nov-Dec;26(9):1093-4. doi: 10.1097/01.iae.0000254896.78766.74.
4
Choroidal neovascularization treated with intravitreal injection of bevacizumab (Avastin) in angioid streaks.玻璃体内注射贝伐单抗（阿瓦斯汀）治疗血管样条纹中的脉络膜新生血管形成
Acta Ophthalmol Scand. 2006 Dec;84(6):835-6. doi: 10.1111/j.1600-0420.2006.00762.x.
5
Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab.玻璃体腔注射贝伐单抗治疗病理性近视性脉络膜新生血管
Retina. 2006 Oct;26(8):960-3. doi: 10.1097/01.iae.0000240121.28034.c3.
6
Clinical and histological findings after intravitreal injection of bevacizumab (Avastin) in a porcine model of choroidal neovascularization.眼内注射贝伐单抗（阿瓦斯汀）治疗脉络膜新生血管的临床和组织学观察。
Acta Ophthalmol. 2010 May;88(3):300-8. doi: 10.1111/j.1755-3768.2008.01439.x. Epub 2010 Mar 19.
7
Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia.玻璃体内注射贝伐单抗治疗年龄相关性黄斑变性或病理性近视继发脉络膜新生血管后房水血管内皮生长因子和色素上皮衍生因子水平的变化
Retina. 2008 Oct;28(9):1308-13. doi: 10.1097/IAE.0b013e31818358b2.
8
Early loss of pregnancy after intravitreal bevacizumab injection.玻璃体内注射贝伐单抗后早期妊娠丢失
Acta Ophthalmol. 2010 Jun;88(4):e136. doi: 10.1111/j.1755-3768.2009.01572.x. Epub 2009 Sep 9.
9
Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.玻璃体腔内注射贝伐单抗治疗年龄相关性黄斑变性继发脉络膜新生血管
Retina. 2006 Apr;26(4):383-90. doi: 10.1097/01.iae.0000238561.99283.0e.
10
Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.玻璃体内注射贝伐单抗（阿瓦斯汀）治疗新生血管性年龄相关性黄斑变性后视网膜色素上皮撕裂
Retina. 2007 Jun;27(5):535-40. doi: 10.1097/IAE.0b013e3180cc2645.
引用本文的文献
1
An study on the effect of bevacizumab on endothelial cell proliferation and VEGF concentration level in patients with hereditary hemorrhagic telangiectasia.一项关于贝伐单抗对遗传性出血性毛细血管扩张症患者内皮细胞增殖及血管内皮生长因子浓度水平影响的研究。
Exp Ther Med. 2022 Jul 5;24(3):555. doi: 10.3892/etm.2022.11493. eCollection 2022 Sep.
2
Hydrophilic Lens Opacification after Intravitreal Anti-VEGF Injections: A Case Series.玻璃体内抗VEGF注射后亲水透镜混浊：病例系列
Case Rep Ophthalmol. 2022 Mar 17;13(1):134-140. doi: 10.1159/000520356. eCollection 2022 Jan-Apr.
3
Intravitreal anti-VEGF agents and cardiovascular risk.玻璃体内抗血管内皮生长因子药物与心血管风险。
Intern Emerg Med. 2020 Mar;15(2):199-210. doi: 10.1007/s11739-019-02253-7. Epub 2019 Dec 17.
4
Plasma-activated medium suppresses choroidal neovascularization in mice: a new therapeutic concept for age-related macular degeneration.血浆激活介质抑制小鼠脉络膜新生血管形成：一种针对年龄相关性黄斑变性的新治疗理念。
Sci Rep. 2015 Jan 9;5:7705. doi: 10.1038/srep07705.
5
A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard.贝伐单抗和雷珠单抗的安全性回顾和荟萃分析：超适应证与金标准。
PLoS One. 2012;7(8):e42701. doi: 10.1371/journal.pone.0042701. Epub 2012 Aug 3.
6
Treatment of age-related macular degeneration: focus on ranibizumab.年龄相关性黄斑变性的治疗：聚焦于雷珠单抗
Clin Ophthalmol. 2008 Mar;2(1):1-14. doi: 10.2147/opth.s1959.
7
Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?贝伐单抗用于治疗年龄相关性黄斑变性的超说明书用药：证据是什么？
Drugs Aging. 2009;26(4):295-320. doi: 10.2165/00002512-200926040-00002.
8
Electrophysiological evaluation of retinal photoreceptor function after repeated bevacizumab injections.多次注射贝伐单抗后视网膜光感受器功能的电生理评估
Doc Ophthalmol. 2009 Apr;118(2):81-8. doi: 10.1007/s10633-008-9136-7. Epub 2008 Jun 20.
9
[Age-related macular degeneration and risk of stroke].[年龄相关性黄斑变性与中风风险]
J Fr Ophtalmol. 2008 Jan;31(1):111-25. doi: 10.1016/s0181-5512(08)70343-7.
10
Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients.贝伐单抗（阿瓦斯汀）治疗中的安全性监测：通过心理物理学（视野、色觉）和电生理学（视网膜电图/眼电图）测试对两组患者亚组的视网膜功能进行评估。
Int Ophthalmol. 2008 Apr;28(2):101-9. doi: 10.1007/s10792-007-9122-1. Epub 2007 Jul 20.
本文引用的文献
1
Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab.玻璃体内注射贝伐单抗治疗的眼部前房炎症活性评估。
Retina. 2006 Oct;26(8):877-81. doi: 10.1097/01.iae.0000237080.10627.b7.
2
The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide.国际玻璃体腔内注射贝伐单抗安全性调查：利用互联网评估全球药物安全性。
Br J Ophthalmol. 2006 Nov;90(11):1344-9. doi: 10.1136/bjo.2006.099598. Epub 2006 Jul 19.
3
Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model.兔模型中玻璃体内注射贝伐单抗不存在组织学视网膜毒性。
Am J Ophthalmol. 2006 Jul;142(1):162-4. doi: 10.1016/j.ajo.2006.03.058.
4
Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.玻璃体内注射贝伐单抗用于治疗年龄相关性黄斑变性中的脉络膜新生血管。
Am J Ophthalmol. 2006 Jul;142(1):1-9. doi: 10.1016/j.ajo.2006.02.037.
5
Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.玻璃体内注射贝伐单抗（阿瓦斯汀）治疗新生血管性年龄相关性黄斑变性的短期安全性和疗效
Retina. 2006 May-Jun;26(5):495-511. doi: 10.1097/01.iae.0000225766.75009.3a.
6
Effects of bevacizumab on retinal function in isolated vertebrate retina.贝伐单抗对离体脊椎动物视网膜功能的影响。
Br J Ophthalmol. 2006 Sep;90(9):1178-82. doi: 10.1136/bjo.2006.094995. Epub 2006 Jun 5.
7
Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.聚乙二醇化重组人血管内皮生长因子受体1拮抗剂钠治疗新生血管性年龄相关性黄斑变性：两项前瞻性、多中心、对照临床试验的两年安全性结果
Ophthalmology. 2006 Jun;113(6):992-1001.e6. doi: 10.1016/j.ophtha.2006.02.027. Epub 2006 Apr 27.
8
Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.玻璃体腔内注射贝伐单抗治疗年龄相关性黄斑变性继发脉络膜新生血管
Retina. 2006 Apr;26(4):383-90. doi: 10.1097/01.iae.0000238561.99283.0e.
9
Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study.玻璃体内注射贝伐单抗（阿瓦斯汀）治疗视网膜中央静脉阻塞所致黄斑水肿的短期研究。
Retina. 2006 Mar;26(3):279-84. doi: 10.1097/00006982-200603000-00005.
10
Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.玻璃体内注射贝伐单抗（阿瓦斯汀）治疗增殖性糖尿病视网膜病变合并玻璃体积血。
Retina. 2006 Mar;26(3):275-8. doi: 10.1097/00006982-200603000-00004.
Zotero 插件